SMALL MOLECULES FOR USE IN PREVENTING AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES

KEYWORDS


Human skin allergens, Nrf2 pathway, neurodegenerative diseases, Alzheimer's Disease, treatment

TECHNOLOGY DESCRIPTION

A panel of **skin allergens** or their derivatives, which exhibit extreme or strong capacity in **neuroprotection by targeting the Nrf2 signalling pathway**, for the treatment and/or prevention of neurodegenerative diseases, namely **Alzheimer's Disease (AD)**.

Improvements:

- electrophilic properties that activates Nrf2, inducing the transcription of several protective genes
- no pain
- intranasal administration
- ability to cross the blood brain barrier
- increase antioxidant genes and decrease pro-inflammatory genes
- induce the translocation on Nrf2 transcription factor into the nucleus and its activation
- decrease the gene and the protein levels of iNOS and IL-1 β
- induce a decrease in NO levels, an anti-inflammatory role
- low levels of Aβ peptides
 - improves cognition in a trangenic mouse model of AD



Application of the molecules for activating the the Nrf2 signalling pathway for the treatment and/or prevention Alzheimer's Disease (AD).

ADVANTAGES OVER ALTERNATIVE TECHNOLOGIES

There are no drugs for the treatment of Alzheimer's disease Only aducanab can be a competitor. However, it has modest clinical results

APPLICATIONS

Alzheimer's Disease and other neurodegenerative diseases: - treatment and/or prevention

CONTACTS

Center for Neuroscience and Cell Biology - Technology Transfer Office Catarina Cunha Santos, PhD - TTO Phone: +351 239 820 190 E-mail: <u>anacunhasantos@cnc.uc.pt / techtransfer@cnc.uc.pt</u>